Vanguard Global Advisers’s BioAtla BCAB Stock Holding History

Vanguard Global Advisers’s Portfolio BCAB Stock Details BCAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-333	Closed	-$2.68K	–	3649
2026 Q1	$2.68K	Buy	+333	New	+$3.9K	﹤0.01%	3602

Other funds holding BCAB

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Lido Advisors Los Angeles, California $36.8B AUM 26.6% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Vanguard Global Advisers's BCAB Position: Q2 2026 in Review

Vanguard Global Advisers sold out of BioAtla (BCAB) in Q2 2026, closing a stake of 333 shares — an estimated $2.68K sold.

Vanguard Global Advisers first reported a position in BCAB in Q1 2026 and held it in 1 quarter. The position peaked at $2.68K in Q1 2026. 19 funds tracked by Wall St. Rank hold BCAB as of Q2 2026.

Vanguard Global Advisers reported no remaining BioAtla position as of Q2 2026 after selling out during the quarter.
Vanguard Global Advisers sold 333 BioAtla shares in Q2 2026, an estimated $2.68K.
Vanguard Global Advisers first reported a position in BioAtla in Q1 2026 and held it in 1 quarter.
Vanguard Global Advisers's BioAtla position peaked at $2.68K in Q1 2026.
19 funds tracked by Wall St. Rank held BioAtla as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.